English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18054/20253 (89%)
Visitors : 24259602      Online Users : 559
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34502

    標題: Simultaneous Reduction of Volume and Dose in Clinical Target Volume for Nasopharyngeal Cancer Patients
    作者: Liu, Wen-Shan
    Tsai, Kuo-Wang
    Kang, Bor-Hwang
    Yang, Ching-Chieh
    Huang, Wei-Lun
    Lee, Ching-Chih
    Hu, Yu-Chang
    Chang, Kuo-Ping
    Chen, Hsiu-Min
    Lin, Yaoh-Shiang
    貢獻者: Kaohsiung Vet Gen Hosp, Dept Radiat Oncol
    Meiho Univ, Dept Nursing
    Natl Def Med Ctr, Sch Med
    Kaohsiung Vet Gen Hosp, Dept Med Educ & Res
    Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Res
    Kaohsiung Vet Gen Hosp, Dept Otorhinolaryngol Head & Neck Surg
    Chi Mei Med Ctr, Dept Radiat Oncol
    Chia Nan Univ Pharm & Sci, Dept Pharm
    Kaohsiung Vet Gen Hosp, Ctr Med Informat, Dept Res
    日期: 2021
    上傳時間: 2023-11-11 11:59:31 (UTC+8)
    摘要: Purpose: To compare the treatment outcome and severe late adverse effects (AEs) between conventional volume and dose (CVD) and simultaneously reduced volume and dose (SRVD) of clinical target volume treatments in patients with nasopharyngeal carcinoma. Methods and Materials: This retrospective cohort study enrolled patients with nonmetastatic stage II to IV nasopharyngeal cancer from a single institute. Survival endpoints and severe (>= grade 3) late AEs and comorbidity were compared between groups. The correlation of severe late AEs, comorbidity, and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression methods. Results: From January 2012 to June 2017, this study enrolled 178 patients, 64 in the CVD group and 114 in the SRVD group. The 2 groups did not differ significantly in patient characteristics except for mean follow-up time (37.6 vs 48.8 months; P = .01). The SRVD group did not significantly differ from the CVD group in local control survival (82.0% vs 78.4%; P = .85), regional control survival (89.9% vs 86.0%; P = .62), or disease-free survival (76.4% vs 66.9%; P = .67). The SRVD group had significantly better OS (93.9% vs 67.0%; P < .001) and salvage survival (79.3% vs 20.7%; P < .01) and a significantly lower ratio of severe lung infection (1 of 113 vs 5 of 59; P = .02). The SRVD group had a significantly lower risk of mortality (hazard ratio [HR], 0.3; P = .03). The factors associated with a significantly higher risk of mortality were N3 (regional lymph node stage status of N3) (HR, 3.0; P = .02); comorbidities of diabetes, coronary artery disease, or chronic kidney disease (grades 2-3) (HR, 3.8; P = .009), and severe lung infection (HR, 6.3; P = .007). Conclusions: Simultaneously reduced volume and dose of clinical target volumes did not impair locoregional control or disease-free survival. The benefits of SRVD treatment may include significant reduction in severe late AEs, particularly lung infection, dysphagia, and xerostomia. However, additional studies with longer patient follow-up are required to confirm these benefits. (C) 2020 Elsevier Inc. All rights reserved.
    關聯: INT J RADIAT ONCOL, v.109, n.2, pp.495-504
    Appears in Collections:[生物科技系(所)] 期刊論文

    Files in This Item:

    File Description SizeFormat

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback